Time to Recurrence(Hormone Receptor-positive Patients)
26182598
25412516
24532400
23612306
22782196
21592075
19951896
18011711
14921396
608547
At risk:AT
Pat
ient
s (%
)
30
25
20
15
10
5
0
0 1 2 3 4 5 6 7 8 9
12.5% 17.0%
21.8%
Follow-up time (years)
9.7%
2.8% 4.8%Absolutedifference
HR+
HR
0.76
95% CI
(0.67, 0.87)
P-value
0.0001
Tamoxifen (T) Anastrozole (A)
Adapted from Forbes J. SABCS 2007.
HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval
Disease-free Survival (Hormone Receptor-positive Patients)
Pat
ient
s (%
)
30
25
20
15
10
5
0
26182598
25412516
24532400
23612306
22782196
21592075
19951896
18011711
14921396
608547
At risk:AT
13.9%
16.4%
25.8%
29.9%
0 1 2 3 4 5 6 7 8 9
Tamoxifen (T) Anastrozole (A)
HR+
HR
0.85
95% CI
(0.76, 0.94)
P-value
0.003
Follow-up time (years)
Absolute difference 2.5% 4.1%
HR=hazard ratio; HR+=hormone receptor-positive; CI=confidence interval
Adapted from Forbes J. SABCS 2007.
Time to Recurrence: Smoothed Hazard Estimates (Hormone Receptor-positive Patients)
Ann
ual h
azar
d ra
tes
(%)
4.0
3.0
2.0
1.0
0.0
0 1 2 3 4 5 6 7 8 9
Follow-up time (years)
Tamoxifen (T) Anastrozole (A)
Adapted from Forbes J. SABCS 2007.
Fracture Episode Rates Throughout the Study
29842976
At risk:
AT
28592824
27452699
26402572
24962419
23062208
20772000
17131645
702659
Time since randomization (years)
Ann
ual f
ract
ure
epis
ode
rate
s (%
)Tamoxifen (T) Anastrozole (A)
0 1 2 3 4 5 6 7 8 90
2
3
4
1
Adapted from Forbes J. SABCS 2007.
Benefits Continue and Detrimental Effects Decline After Treatment Cessation
Time to recurrence Fracture episode rates
Pa
tien
ts (
%)
30
25
20
15
10
5
00 1 2 3 4 5 6 7 8 9
12.5%17.0%
21.8%
Follow-up time (years)
9.7%
2.8% 4.8%Absolutedifference
Tamoxifen (T)Anastrozole (A)
Time since randomization (years)
An
nu
al f
ract
ure
ep
iso
de
ra
tes
(%) Tamoxifen (T)
Anastrozole (A)
0 1 2 3 4 5 6 7 8 90
2
3
4
1
Adapted from Forbes J. SABCS 2007.
Recommended
